CA2174244A1 - Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules - Google Patents

Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules

Info

Publication number
CA2174244A1
CA2174244A1 CA002174244A CA2174244A CA2174244A1 CA 2174244 A1 CA2174244 A1 CA 2174244A1 CA 002174244 A CA002174244 A CA 002174244A CA 2174244 A CA2174244 A CA 2174244A CA 2174244 A1 CA2174244 A1 CA 2174244A1
Authority
CA
Canada
Prior art keywords
composition
pairs
matter according
particles
core particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002174244A
Other languages
English (en)
Inventor
Nir Kossovsky
Edward Sponsler
Andrew Gelman
H. James Hnatyszyn
Samir Rajguru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/145,870 external-priority patent/US5460830A/en
Priority claimed from US08/146,536 external-priority patent/US5462751A/en
Priority claimed from US08/147,751 external-priority patent/US5460831A/en
Application filed by Individual filed Critical Individual
Publication of CA2174244A1 publication Critical patent/CA2174244A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition à activité biologique qui comprend des particules noyaux ou des surfaces qui sont recouvertes d'une couche favorisant la fixation de paires à réaction biochimique (BRP) sans les dénaturer. Les BRP susceptibles d'être fixées comprennent les paires ligand-récepteur, les paires enzyme-substrat, les paires médicament-récepteur, les paires catalyseur-réactant, les paires toxine-ligand, les paires absorbant-absorbat et les paires adsorbant-adsorbat. L'invention concerne en outre des compositions à activité biologique composées de particules noyaux biodégradables recouvertes d'une couche destinée à favoriser la fixation d'agents à activité biologique sans les dénaturer. Ces compositions peuvent également contenir une membrane extérieure de ciblage qui confère un ciblage sélectif aux récepteurs spécifiques. L'invention concerne par ailleurs des compositions à activité biologique qui s'utilisent en thérapie génique, ainsi que d'autres procédés de transfection. Ces compositions comprennent des particules noyaux nanocristallines qui sont recouvertes d'une couche destinée à favoriser la fixation d'agents de transfection (segments d'ADN/d'ARN et fragments anti-sens) sans les dénaturer. Ces compositions peuvent en outre contenir une membrane extérieure de ciblage qui confère un ciblage sélectif des agents de transfection aux récepteurs de cellules spécifiques.
CA002174244A 1993-11-01 1994-10-31 Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules Abandoned CA2174244A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/145,870 US5460830A (en) 1990-06-22 1993-11-01 Biochemically active agents for chemical catalysis and cell receptor activation
US08/146,536 US5462751A (en) 1990-06-22 1993-11-01 Biological and pharmaceutical agents having a nanomeric biodegradable core
US08/146,536 1993-11-01
US08/145,870 1993-11-01
US08/147,751 US5460831A (en) 1990-06-22 1993-11-04 Targeted transfection nanoparticles
US08/147,751 1993-11-04

Publications (1)

Publication Number Publication Date
CA2174244A1 true CA2174244A1 (fr) 1995-05-11

Family

ID=27386330

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002174244A Abandoned CA2174244A1 (fr) 1993-11-01 1994-10-31 Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules

Country Status (4)

Country Link
EP (1) EP0726767A4 (fr)
JP (1) JPH09504790A (fr)
CA (1) CA2174244A1 (fr)
WO (1) WO1995012392A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5811274A (en) * 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
CA2223921A1 (fr) * 1995-06-07 1996-12-19 Francis C. Szoka, Jr. Stabilisation de complexes de polynucleotides
JP2000503000A (ja) * 1995-12-21 2000-03-14 クエスト・インターナショナル・ビー・ブイ 粒状組成物
WO1999030741A2 (fr) * 1997-12-12 1999-06-24 Max-Delbrück-Centrum für Molekulare Medizin Agent pour la therapie genique de tumeurs, maladies neurodegeneratives, cardiovasculaires et auto-immunes
KR20010040747A (ko) * 1998-02-09 2001-05-15 다나베 히로까즈 디엔에이를 고정화해서 증폭하기 위한 기질, 그 기질에디엔에이를 고정화한 디엔에이고정화칩 및 디엔에이를증폭하는 방법
JP4001710B2 (ja) * 2000-10-18 2007-10-31 東洋鋼鈑株式会社 分離精製・抽出用粒子状担体及びその製造方法
WO2006050368A2 (fr) * 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium destinees a la medecine esthetique ou cosmetique, et procedes de fabrication et d'utilisation
ES2557183B1 (es) * 2014-07-21 2016-11-03 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de nanopartículas de fosfato de calcio amorfo recubiertas de citrato y dopadas con flúor
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
JP2018519838A (ja) * 2015-07-15 2018-07-26 ザイムトロニクス エルエルシーＺｙｍｔｒｏｎｉｘ， Ｌｌｃ 自動バイオナノ触媒製造
CA3031802A1 (fr) 2016-08-13 2018-02-22 Zymtronix Catalytic Systems, Inc. Enzymes biocides immobilisees magnetiquement et produits chimiques biocides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093757A1 (fr) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Nanosphere ou nanoparticule a sensibilite magnetique, pouvant etre administree de maniere intravasculaire, son procede de production et son utilisation
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5306508A (en) * 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes

Also Published As

Publication number Publication date
JPH09504790A (ja) 1997-05-13
EP0726767A1 (fr) 1996-08-21
EP0726767A4 (fr) 1997-08-20
WO1995012392A1 (fr) 1995-05-11

Similar Documents

Publication Publication Date Title
US5462751A (en) Biological and pharmaceutical agents having a nanomeric biodegradable core
US5460830A (en) Biochemically active agents for chemical catalysis and cell receptor activation
US5460831A (en) Targeted transfection nanoparticles
US5334394A (en) Human immunodeficiency virus decoy
US5178882A (en) Viral decoy vaccine
US5219577A (en) Biologically active composition having a nanocrystalline core
US5464634A (en) Red blood cell surrogate
CA2174244A1 (fr) Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules
US7855180B2 (en) Structure and method for releasing substance therefrom
Kossovsky et al. Surface-modified nanocrystalline ceramics for drug delivery applications
Jain et al. Aquasomes: A novel drug carrier
US5306508A (en) Red blood cell surrogate
Cheng et al. Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy
Gitman et al. Targeting of loaded Sendai virus envelopes by covalently attached insulin molecules to virus receptor-depleted cells: fusion-mediated microinjection of ricin A and simian virus 40 DNA.
CN114452266B (zh) 一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用
JP4965022B2 (ja) 安定化されたタンパク質結晶、それを含む処方物、およびそれを作製する方法
Grimaldi et al. Engineered liposomes and virosomes for delivery of macromolecules
WO2000007630A1 (fr) Administration d'acide nucleique
CN115869418B (zh) 一种调控血清蛋白冠形成的金纳米颗粒、其制备方法和应用
CN110540589B (zh) 一种多肽、多肽修饰的脂质载体及应用
Rane et al. Aquasomes: A nanocarrier system

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead